Immuneering is expanding atebimetinib into three new trials, including a potentially registrational Phase 2 study in anaplastic thyroid cancer. Two AstellasUS-s

Immuneering is expanding atebimetinib into three new trials, including a potentially registrational Phase 2 study in anaplastic thyroid cancer. Two AstellasUS-sponsored studies will target CLDN18.2-expressing pancreatic cancer; new data are due at ENA2026.